Esophagitis, Reflux Clinical Trial
Official title:
A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis.
The purpose of this study is to assess the ability of once-daily (QD) treatment with dexlansoprazole modified release (MR) 30 mg and 60 mg or placebo in maintaining healing of erosive esophagitis (EE).
This is a Phase 3, randomized, double-blind, multicenter, placebo-controlled, 6 month maintenance study. The study is designed to compare the efficacy and safety of daily dexlansoprazole MR (30 mg and 60 mg) with that of placebo, in maintaining healing of EE. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02463643 -
To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis
|
Phase 2 | |
| Completed |
NCT00255164 -
Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis
|
Phase 3 | |
| Completed |
NCT00255151 -
Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
|
Phase 3 | |
| Suspended |
NCT00282555 -
Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis
|
Phase 2 | |
| Completed |
NCT00251693 -
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
|
Phase 3 | |
| Completed |
NCT00251719 -
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
|
Phase 3 | |
| Not yet recruiting |
NCT05418920 -
Clinical Trial of Reconstruction After Proximal Gastrectomy
|
N/A | |
| Recruiting |
NCT02049723 -
Assessment of GERD Knowledge Level Among Patients With it in Korea
|
N/A |